Clinical observation of glucocorticoid combined with compoundα-keto acids therapy in primary nephrotic syndrome

WANG Ya-li; WANG Jian-sheng

doi:10.3969/j.issn.1006-5725.2015.19.021

Abstract：Objective To investigate the therapeutic effect and safety of glucocorticoid combined with compoundα-keto acids therapy in primary nephrotic syndrome. Methods A prospective randomized controlled trial was carried out.Seventy-two cases of primary nephrotic syndrome were equally divided into treatment group and control group. Two groups of patients were both treated with glucocorticoids , and combined with compoundα-keto acid tablets in the treatment group. The level of BUN ,Scr,CRP,IL-6,PA、Alb,TG,TC,Ca in blood and eGFR、MTP were detected before treatment and the 2nd,4th,6th,8th month after treatment to evaluate the efficacy and safety respectively. Results After 8 months of treatment, the total effective rate in treatment group was significantly higher than that in the control group (P < 0.05); Compared with before treatment, the Alb level was significantly increased in both groups, the level of MTP,TC,TG,PA,CRP,IL-6 were significantly declined in both groups (P < 0.05),while no significant difference was found in the level of BUN,Scr,eGFR,serum calcium in both groups(P > 0.05); the level of MTP,TC,TG,CRP、IL-6 in the treatment group were significantly lower and the Alb level in the treatment group was significantly higher (P < 0.05)compared with the control group, while no significant difference was found in the level of PA、BUN、Scr、eGFR、serum calcium (P > 0.05) between two groups;All of patients with no serious adverse reactions occurred during the investigation. Conclusion The curative effect of glucocorticoid combined with compoundα-keto acids therapy in primary nephrotic syndrome is sure and without significant sideeffect.